Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Rizvi NA, et al. Among authors: peters s. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. JAMA Oncol. 2020. PMID: 32271377 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M. Stupp R, et al. Among authors: peters s. Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13. Lancet Oncol. 2009. PMID: 19604722 Clinical Trial.
Therapeutic advances in non-small cell lung cancer.
Vallières E, Peters S, Van Houtte P, Dalal P, Lim E. Vallières E, et al. Among authors: peters s. Thorax. 2012 Dec;67(12):1097-101. doi: 10.1136/thoraxjnl-2011-201043. Epub 2011 Nov 5. Thorax. 2012. PMID: 22058187 Review.
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Mazières J, et al. Among authors: peters s. J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610105
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Peters S, et al. J Thorac Oncol. 2014 Nov;9(11):1675-84. doi: 10.1097/JTO.0000000000000320. J Thorac Oncol. 2014. PMID: 25436801 Free article.
3,618 results